Literature DB >> 20848406

Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis.

Sang-Heng Kok1, Hao-Hueng Chang, Ju-Yi Tsai, Hsin-Chia Hung, Chiao-Ying Lin, Chun-Pin Chiang, Cheing-Meei Liu, Mark Yen-Ping Kuo.   

Abstract

BACKGROUND: Cysteine-rich 61 (Cyr61 [CCN1]) has disparate functions in tumorigenesis that are dependent on the cell types. The aim of the study was to investigate its role in the growth of oral squamous cell carcinoma (SCC).
METHODS: The study used immunohistochemistry to examine Cyr61 expression in 93 oral SCC specimens and assessed the effect of Cyr61 overexpression on proliferation and migration of oral SCC cells in vitro and xenograft growth in severe combined immunodeficient (SCID) mice.
RESULTS: High expression of Cyr61 significantly correlated with large tumor size (p = .009) and advanced tumor stage (p = .036). Multivariate analysis revealed that high Cyr61 (relative risk [RR] 2.44, 95% confidence interval [CI] 1.209-4.95, p = .010) significantly correlated with mortality. Forced expression of Cyr61 stimulated the motility and growth of Ca9-22 cells in vitro and enhanced xenograft growth in SCID mice.
CONCLUSIONS: Cyr61 is a positive growth modulator of oral SCC and Cyr61 overexpression is an independent prognostic indicator for patients with oral SCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20848406     DOI: 10.1002/hed.21381

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

Review 1.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 2.  CCN1/CYR61: the very model of a modern matricellular protein.

Authors:  Lester F Lau
Journal:  Cell Mol Life Sci       Date:  2011-07-31       Impact factor: 9.261

3.  Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.

Authors:  Y F Song; Z B Xu; X J Zhu; X Tao; J L Liu; F L Gao; C L Wu; B Song; Q Lin
Journal:  Clin Transl Oncol       Date:  2016-10-14       Impact factor: 3.405

4.  SUOX is negatively associated with multistep carcinogenesis and proliferation in oral squamous cell carcinoma.

Authors:  Ken Nakamura; Jun Akiba; Sachiko Ogasawara; Yoshiki Naito; Masamichi Nakayama; Yushi Abe; Jingo Kusukawa; Hirohisa Yano
Journal:  Med Mol Morphol       Date:  2017-12-26       Impact factor: 2.309

Review 5.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis.

Authors:  Tsu-Yao Cheng; Ming-Shiang Wu; Kuo-Tai Hua; Min-Liang Kuo; Ming-Tsan Lin
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.

Authors:  Robert L Mango; Qing Ping Wu; Michelle West; Everett C McCook; Jonathan S Serody; Hendrik W van Deventer
Journal:  Mol Cancer Res       Date:  2013-11-06       Impact factor: 5.852

7.  RASSF1A-Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target.

Authors:  Madhuram Khandelwal; Vivek Anand; Sandeep Appunni; Amlesh Seth; Prabhjot Singh; Sandeep Mathur; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2019-11-21       Impact factor: 3.396

8.  Cyr61 expression is associated with prognosis in patients with colorectal cancer.

Authors:  Dongjun Jeong; Suhak Heo; Tae Sung Ahn; Sookyoung Lee; Soyoung Park; Hyungjoo Kim; Doosan Park; Sang Byung Bae; Sung Soo Lee; Moon Soo Lee; Chang-Jin Kim; Moo Jun Baek
Journal:  BMC Cancer       Date:  2014-03-07       Impact factor: 4.430

9.  Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma.

Authors:  Manabu Shigeoka; Naoki Urakawa; Mari Nishio; Nobuhisa Takase; Soken Utsunomiya; Hiroaki Akiyama; Yoshihiro Kakeji; Takahide Komori; Yu-ichiro Koma; Hiroshi Yokozaki
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

10.  Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.

Authors:  Masaaki Yasukawa; Hisako Fujihara; Hiroaki Fujimori; Koji Kawaguchi; Hiroyuki Yamada; Ryoko Nakayama; Nanami Yamamoto; Yuta Kishi; Yoshiki Hamada; Mitsuko Masutani
Journal:  Int J Mol Sci       Date:  2016-02-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.